MedTrace Logo

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

NCT00513188 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-12-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to non-Hodgkin lymphoma cells. Giving combination chemotherapy together with denileukin diftitox may kill more cancer cells.

PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with denileukin diftitox works in treating patients with newly diagnosed T-cell non-Hodgkin lymphoma.

Conditions

Interventions

BIOLOGICAL

denileukin diftitox

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

doxorubicin hydrochloride

DRUG

leucovorin calcium

DRUG

methotrexate

DRUG

prednisone

DRUG

vincristine sulfate

GENETIC

protein expression analysis

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Maricer Escalon, MD, MS · University of Miami Sylvester Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513188 on ClinicalTrials.gov